ReproCell

ReproCell Altman Z-Score

The Altman Z-Score of ReproCell (4978.T) as of Oct 9, 2026 is 11.37. In the previous year, Altman Z-Score was 13.79 — a change of -17.56% (lower).

Altman Z-Score

11.37

YoY

-17.56%

Last updated:

Altman Z-Score of ReproCell is 2026 11.37 . Altman Z-Score of ReproCell was 2025 13.79 . It decreases by -17.56% lower compared to the previous year.

The ReproCell Altman Z-Score history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Altman Z-Score
Date
Altman Z-Score
Jan 1, 2019
20.58 JPY
Jan 1, 2020
16.70 JPY
Jan 1, 2021
11.67 JPY
Jan 1, 2022
10.86 JPY
Jan 1, 2023
12.00 JPY
Jan 1, 2024
12.54 JPY
Jan 1, 2025
13.79 JPY
Jan 1, 2026
11.37 JPY
The ReproCell Altman Z-Score history
YEARAltman Z-ScoreYoY
11.37-17.56%
13.79+9.93%
12.54+4.52%
12.00+10.52%
10.86-6.96%
11.67-30.11%
16.70-18.88%
20.58-16.85%
24.75+37.07%
18.06+46.55%
12.32-30.33%
17.69-57.12%
41.25—
Access this data via the Eulerpool API

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

Altman Z-Score of ReproCell is 11.37 in 2026.

On Eulerpool you can find the complete historical development of Altman Z-Score ReproCell since 2006 – with annual values, charts, and detailed analysis.

The Altman Z-Score predicts bankruptcy probability using five financial ratios. Scores above 3.0 indicate safety, below 1.8 suggests distress risk.

Access this data via the Eulerpool API

Quality — ReproCell

All Key Metrics — ReproCell